- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion: A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men (clinicaltrials.gov) - Sep 1, 2021
P1, N=43, Completed,
Recruiting --> Completed
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial suspension, Combination therapy: SERENE: Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy (clinicaltrials.gov) - Jul 12, 2021
P3, N=900, Suspended,
Recruiting --> Completed Recruiting --> Suspended
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion: SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain (clinicaltrials.gov) - Jun 28, 2021
P3, N=638, Completed,
Recruiting --> Suspended Active, not recruiting --> Completed
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion: SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain (clinicaltrials.gov) - Jun 28, 2021
P3, N=623, Completed,
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment open, Combination therapy: SERENE: Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy (clinicaltrials.gov) - Mar 24, 2021
P3, N=900, Recruiting,
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion date: Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (clinicaltrials.gov) - Mar 23, 2021
P3, N=229, Active, not recruiting,
Not yet recruiting --> Recruiting Trial completion date: Aug 2021 --> Mar 2022
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
New P3 trial, Combination therapy: SERENE: Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy (clinicaltrials.gov) - Feb 15, 2021
P3, N=900, Not yet recruiting,
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion: LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (clinicaltrials.gov) - Jan 25, 2021
P3, N=477, Completed,
Trial completion date: Aug 2021 --> Mar 2022 Active, not recruiting --> Completed
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
New P1 trial: A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men (clinicaltrials.gov) - Jan 18, 2021
P1, N=40, Recruiting,
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion, Trial completion date: LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (clinicaltrials.gov) - Oct 19, 2020
P3, N=382, Completed,
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Sep 2020
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion date: SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain (clinicaltrials.gov) - Oct 12, 2020
P3, N=623, Active, not recruiting,
Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Sep 2020 Trial completion date: Sep 2020 --> Mar 2021
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion, Trial completion date: LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (clinicaltrials.gov) - Sep 2, 2020
P3, N=388, Completed,
Trial completion date: Sep 2020 --> Mar 2021 Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Aug 2020
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion date, Trial primary completion date: SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain (clinicaltrials.gov) - Aug 12, 2020
P3, N=803, Active, not recruiting,
Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Aug 2020 Trial completion date: Mar 2022 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion date: SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain (clinicaltrials.gov) - Aug 8, 2020
P3, N=638, Active, not recruiting,
Trial completion date: Mar 2022 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2021 Trial completion date: Nov 2020 --> May 2021
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion date: LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (clinicaltrials.gov) - Jul 16, 2020
P3, N=477, Active, not recruiting,
Trial completion date: Nov 2020 --> May 2021 Trial completion date: Jul 2020 --> Mar 2021
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion date: SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain (clinicaltrials.gov) - Jun 28, 2020
P3, N=623, Active, not recruiting,
Trial completion date: Jul 2020 --> Mar 2021 Trial completion date: Jun 2020 --> Sep 2020
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion date: LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (clinicaltrials.gov) - Jun 23, 2020
P3, N=382, Active, not recruiting,
Trial completion date: Jun 2020 --> Sep 2020 Trial completion date: Aug 2020 --> Dec 2020
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion date: LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (clinicaltrials.gov) - Jun 23, 2020
P3, N=388, Active, not recruiting,
Trial completion date: Aug 2020 --> Dec 2020 Trial completion date: Jun 2020 --> Dec 2020
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion date: SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain (clinicaltrials.gov) - Jun 17, 2020
P3, N=600, Active, not recruiting,
Trial completion date: Jun 2020 --> Dec 2020 Trial completion date: Jun 2020 --> Nov 2020
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment closed: SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain (clinicaltrials.gov) - Jun 17, 2020
P3, N=803, Active, not recruiting,
Trial completion date: Jun 2020 --> Nov 2020 Enrolling by invitation --> Active, not recruiting
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion date: LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (clinicaltrials.gov) - Mar 10, 2020
P3, N=390, Active, not recruiting,
Enrolling by invitation --> Active, not recruiting Trial completion date: Apr 2020 --> Aug 2020
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial primary completion date: SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain (clinicaltrials.gov) - Feb 23, 2020
P3, N=600, Active, not recruiting,
Trial completion date: Apr 2020 --> Aug 2020 Trial primary completion date: Dec 2019 --> Apr 2020
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment closed, Trial primary completion date: SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain (clinicaltrials.gov) - Feb 20, 2020
P3, N=600, Active, not recruiting,
Trial primary completion date: Dec 2019 --> Apr 2020 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2019 --> Jun 2020
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (clinicaltrials.gov) - Feb 5, 2020
P3, N=229, Active, not recruiting,
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2019 --> Jun 2020 Enrolling by invitation --> Active, not recruiting | N=360 --> 229 | Trial completion date: Mar 2021 --> Aug 2021 | Trial primary completion date: Aug 2020 --> Feb 2021
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment open: SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain (clinicaltrials.gov) - Aug 26, 2019
P3, N=600, Recruiting,
Enrolling by invitation --> Active, not recruiting | N=360 --> 229 | Trial completion date: Mar 2021 --> Aug 2021 | Trial primary completion date: Aug 2020 --> Feb 2021 Active, not recruiting --> Recruiting
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment closed: SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain (clinicaltrials.gov) - Aug 20, 2019
P3, N=600, Active, not recruiting,
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial primary completion date: LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (clinicaltrials.gov) - Jul 16, 2019
P3, N=390, Active, not recruiting,
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2019 --> Jun 2019
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment closed: LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (clinicaltrials.gov) - Jul 16, 2019
P3, N=600, Active, not recruiting,
Trial primary completion date: Sep 2019 --> Jun 2019 Enrolling by invitation --> Active, not recruiting
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion date: SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain (clinicaltrials.gov) - Jan 18, 2019
P3, N=800, Enrolling by invitation,
Enrolling by invitation --> Active, not recruiting Trial completion date: Mar 2021 --> Mar 2022
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
New P3 trial: Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (clinicaltrials.gov) - Nov 23, 2018
P3, N=360, Enrolling by invitation,
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment closed, Trial completion date, Trial initiation date, Trial primary completion date: LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (clinicaltrials.gov) - Nov 20, 2018
P3, N=390, Active, not recruiting,
Trial completion date: Mar 2021 --> Mar 2022 Recruiting --> Active, not recruiting | Trial completion date: Jun 2019 --> Dec 2019 | Initiation date: Jan 2017 --> Apr 2017 | Trial primary completion date: Dec 2018 --> Jun 2019
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment closed, Trial completion date, Trial primary completion date: LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (clinicaltrials.gov) - Nov 20, 2018
P3, N=390, Active, not recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Jun 2019 --> Dec 2019 | Initiation date: Jan 2017 --> Apr 2017 | Trial primary completion date: Dec 2018 --> Jun 2019 Recruiting --> Active, not recruiting | Trial completion date: Jun 2019 --> Feb 2020 | Trial primary completion date: Dec 2018 --> Sep 2019
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion date, Trial primary completion date: LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (clinicaltrials.gov) - Nov 20, 2018
P3, N=600, Enrolling by invitation,
Recruiting --> Active, not recruiting | Trial completion date: Jun 2019 --> Feb 2020 | Trial primary completion date: Dec 2018 --> Sep 2019 Trial completion date: Jan 2020 --> Jul 2020 | Trial primary completion date: Jul 2019 --> Feb 2020
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial initiation date: SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain (clinicaltrials.gov) - Nov 15, 2018
P3, N=600, Recruiting,
Trial completion date: Jan 2020 --> Jul 2020 | Trial primary completion date: Jul 2019 --> Feb 2020 Initiation date: Jun 2017 --> Dec 2017
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
New P3 trial: SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain (clinicaltrials.gov) - Aug 31, 2018
P3, N=800, Enrolling by invitation,
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
New P3 trial: LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (clinicaltrials.gov) - Jan 29, 2018
P3, N=600, Enrolling by invitation,
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment open: SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain (clinicaltrials.gov) - Sep 11, 2017
P3, N=600, Recruiting,
Initiation date: Jun 2017 --> Dec 2017 Not yet recruiting --> Recruiting
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment open, Trial initiation date: SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain (clinicaltrials.gov) - Sep 11, 2017
P3, N=600, Recruiting,
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Jun 2017 --> Aug 2017
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
New P3 trial: SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain (clinicaltrials.gov) - Jul 2, 2017
P3, N=600, Not yet recruiting,
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
New P3 trial: SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain (clinicaltrials.gov) - Jul 2, 2017
P3, N=600, Not yet recruiting,
- |||||||||| Myfembree (relugolix/estradiol/norethindrone acetate) / Sumitomo Pharma, Pfizer, ASKA Pharma, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
New P3 trial: LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (clinicaltrials.gov) - Feb 10, 2017
P3, N=390, Recruiting,
|
